Key result
COVID-19 recovery linked to ~35% higher risk of new-onset heart failure.
Why the study?
While acute cardiac injury during COVID-19 is well documented, the long-term risk of new-onset heart failure in survivors remains a critical clinical concern.
Does COVID-19 recovery increase the risk of new-onset heart failure in survivors?
Does COVID-19 recovery increase the risk of new-onset heart failure in survivors?
COVID-19 recovery is associated with a 35% increased risk of new-onset heart failure over a 25-month follow-up, highlighting the need for long-term cardiovascular monitoring in survivors.
No takes yet. Share an insight, caveat, or question.
May warrant long-term HF monitoring after COVID-19; extends evidence to transplant recipients and younger adults.
Background/Objectives: While acute cardiac injury during COVID-19 is well-documented, the long-term risk of new-onset heart failure (HF) in survivors remains a critical clinical concern. This study aims to quantify the risk of new-onset heart failure during a 25 months prognostic follow-up period following recovery from SARS-CoV-2. Methods: We conducted a systematic review and meta-analysis of nine high-quality studies (n > 400,000 survivors) in accordance with PRISMA 2020 guidelines. Databases including PubMed/MEDLINE and Scopus were searched through January 2026. A quantitative meta-analysis was performed on six studies using a random-effects model to pool adjusted hazard ratios (aHR). Results: The pooled analysis revealed a significant 35% increased risk of new-onset heart failure following COVID-19 recovery (aHR 1.35; 95% CI: 1.14–1.60; p = 0.001). Significant heterogeneity was observed (I2 = 92.62%), reflecting diverse risk profiles among survivors. The risk was most pronounced in immunocompromised kidney transplant recipients (aHR 2.32) and younger adults under the age of 65 (aHR 1.53). Subclinical myocardial damage, characterized by reduced left ventricular longitudinal strain, was identified even in survivors who experienced mild initial infections. Conclusions: COVID-19 recovery serves as a significant independent risk factor for chronic heart failure, emphasizing that cardiovascular impact extends far beyond the acute phase. These findings necessitate the implementation of structured cardiovascular monitoring and biomarker screening for at least one year post-infection to address this emerging chronic disease burden.
Mihai et al. (2026) studied this question. COVID-19 recovery is associated with a 35% increased risk of new-onset heart failure (aHR 1.35), particularly among kidney transplant recipients and adults under 65.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: